Adding Years to Our Lives
and Life to Our Years
The Longevity Science Foundation funds the world’s most promising early-stage research in geroscience, chronic disease prevention, and women’s health — the science that can move the needle most, and is most chronically underfunded.
Accelerating the Impact of Longevity Science
The Longevity Science Foundation (LSF) is a 501(c)(3) nonprofit that funds innovative, early-stage longevity research, primarily through the lens of geroscience, chronic and age-related disease prevention, and underrepresented population groups in research. Prevention-focused research is critically underfunded not due to the quality of the science, but because profit-driven models have no incentive to fund it. We exist to fill that gap.
Longevity is a right for all people regardless of geography or means. The LSF is committed to ensuring that the benefits of longevity science reach everyone — not just those with access to premium care. That means funding research on underrepresented populations, supporting open-access science, and building a model of philanthropy that is transparent, accountable, and designed to serve people at scale.
Prevention Science is Critically Underfunded
— for the Wrong Reasons
Despite the growth of longevity investment, critical funding gaps remain in the science that can deliver near-term healthspan and lifespan benefits. The global healthspan-lifespan gap has grown from 10.8 to 12.7 years — and without meaningful intervention in how prevention science is funded, that gap will only widen.
More people are living longer with diseases — placing crushing social, economic, and emotional burdens on families and entire economies. Without intervention, this burden will deepen, and health inequities will widen.
Industry Misalignment
The economics of healthcare favor treatment over prevention. Drug development, medical devices, and care management are built around managing disease — not eliminating its root causes. Prevention-focused science, by definition, competes poorly for private capital when the return horizon is long and the addressable market shrinks with success.
Government Underfunding
The National Institute on Aging — where the majority of prevention-focused aging research is housed — receives a fraction of the overall NIH budget, despite aging being the primary driver of the diseases NIH seeks to address. Governments tend to fund incremental extensions of existing science, not the kind of paradigm-shifting breakthroughs that alter disease trajectories.
Academic IP Constraints
Academic institutions pursue commercially viable IP. Early-stage, high-impact science is systematically left without a funding home.
Philanthropy Is the Missing Lever
Industry won’t fund it. Governments move too slowly. Academic institutions are constrained by commercial incentives. Catalytic philanthropy is the only force that can drive prevention science forward — and without it, the gap will only grow.
VC Rigor. Nonprofit Mission.
We identify and fund the most promising prevention and prediction-focused science, using biological aging as the unifying lens to address the root mechanisms of aging and disease. Our diligence process models the rigor of venture capital, but with a nonprofit mission — every decision is guided by impact, not return. By lifting the burden of funding from researchers, we enable them to generate the knowledge and solutions that will allow people to not just live longer, but to live healthier for longer.
Geroscience Research
Geroscience investigates the biological mechanisms of aging and how aging itself increases the risk for chronic and age-related diseases. Understanding these root mechanisms is the foundation of everything we fund.
Chronic & Age-Related Disease Prevention
Billions are spent on treatment and care. Only a tiny fraction goes to prevention and prediction. Our thesis: prevent and predict diseases and their root causes, rather than simply alleviating symptoms after the damage is done.
Underrepresented Populations — Women’s Health
Women bear a disproportionate burden from age-related disease yet represent the most underserved population in biomedical research — with women’s health accounting for only ~8.8% of NIH grant spending over the last decade. By 2030, 1.2 billion women will be menopausal or postmenopausal, facing sharply elevated risks for cardiovascular disease, neurodegeneration, and metabolic decline. This is not a niche concern. It is a population-scale failure with a clear scientific path forward.
Identifying Unique Solutions
Identifying novel research pathways to drive impact on healthspan and lifespan under our three verticals.
Upon receipt of proposals via RFP, multi-layer due diligence and project review by the Head Scientific Analyst and the team are conducted.
The Scientific Advisory Board reviews the final project selection, applying the highest standards of global longevity and geroscience expertise.
The most promising and most impactful research is funded — projects designed to deliver measurable, real-world healthspan and lifespan benefits.
Our diligence process has already identified and funded breakthrough science at two of the world’s leading research universities, with more in the pipeline.
Department of Cellular & Molecular Medicine. Using targeted molecules to eliminate damaged brain cells (senescent astrocytes) to reverse brain aging and combat neurodegenerative diseases.
Department of Physiology, Anatomy & Genetics. Enhancing heart function and longevity by modifying metabolism and diet-related methylation to prevent heart disease — and identifying reversal pathways for cardiac aging.
A woman’s ovaries age at more than double the rate of any other tissue in the body — driving the hormonal cascade that elevates risk for cardiovascular disease, neurodegeneration, bone loss, and metabolic decline. Women with early menopause (before 40) face a ~47% higher hazard of dementia, and late hormone therapy initiation has been associated with a ~105% increase in dementia risk — underscoring that timing and biology are everything.
This grant call targets age-related fertility decline, ovarian aging, hormonal biomarker development, and the biological drivers of the menopausal transition. Our pipeline includes development of a “menopause clock” — a noninvasive, data-driven tool to detect hormonal aging earlier and stratify downstream disease risk before avoidable harm accumulates. RAND analysis suggests that doubling NIH investment in coronary artery disease research in women — from just $20M — would generate a 9,500% ROI to the broader economy. The science is undeniable, the need is urgent, and it is simply the right thing to do.
A Completely Different Approach
Research, Not Commercialization
Other models prioritize commercialization, while we emphasize a strong research thesis, fueling innovation and accelerating the pipeline of high-quality interventions.
Tax Deductibility
LSF is a registered 501(c)(3) nonprofit. Contributions are tax-deductible subject to IRS guidelines and individual circumstances. We encourage donors to consult their tax advisor — and we accept cash, DAF, stock, and cryptocurrency.
Open Access Projects
While others may fund research, we uniquely work with partners to ensure intentional accessibility plans, supporting the democratization of longevity interventions for all people.
Choice Flexibility
Most nonprofits accept unrestricted donations. At LSF, donors become partners, choosing where their support goes across our key focus areas.
Balanced Risk Profile
We build a research portfolio that marries ambition with feasibility — the “sweet spot” between novelty and viability, backing projects with translational potential and new methods.
Ecosystem Support
In collaboration with partners and our global network, LSF is building a robust longevity ecosystem, from research to startups to scalable real-world solutions.
Transactional Transparency
100% of donor contributions go directly to funded research. Foundation operations and overhead are covered by our founders — not your gift. Every dollar you give funds science, not administration.
Near-Term Clinical Relevance
We prioritize applied solutions — diagnostics, AI-driven discovery, therapeutics, and personalized medicine — selected specifically for their potential to accelerate the path from bench to real-world health impact.
We Are the Truth Broker.
In addition to funding high-impact longevity research, we recognize that research only has impact if communities are aware of it. We firmly believe that evidence-based, bias-free education is imperative in unlocking longevity outcomes for all people. At the root of inequity and access in the longevity ecosystem lies a lack of total transparency. We aim to be the truth broker in longevity — educating not only practitioners and clinicians, but the everyday patients we all serve. Our goal is to democratize the power of research without being prescriptive or opinionated. In a world where marketing and profit often take precedence, we stand as champions of fact and science.
A series that unpacks trending longevity topics by separating the hype around them from the actual science and evidence behind their efficacy. Rigorous, accessible, and bias-free.
A look at global trends, scientific breakthroughs, and practical interventions for healthy aging — focused on topics like brain health, female fertility, cardiovascular aging, and more.
Founded by Investors. Built for Impact.
The LSF was built by people who understand both sides of the equation — what the science needs, and what the market won’t fund. That distinction is what makes us structurally different from every other nonprofit in this space.
Successful VC investors in the longevity biotech space, Garri and Sergey founded LSF from a position of hard-won market insight. Investing commercially, they saw the gap firsthand: breakthrough prevention research — the kind that creates the next generation of great companies — was being left unfunded because no profit-driven model had an incentive to touch it. They built LSF to close that gap deliberately: as an act of giving back, and because the need for a rigorous, independent research funder was simply undeniable.
Joshua came from ultra-high-net-worth wealth management at AllianceBernstein, advising family offices and multigenerational families on long-term planning, legacy, and risk. Both of his parents are cancer survivors — giving him a front-row seat to what early research and detection can do. He joined LSF driven by one question: “We spend so much energy building long-term financial plans. Why aren’t we doing the same for our health?” Since joining, LSF has gone from zero funded projects to three — with 2025 donations running 250% ahead of the prior three years combined.
Advised by the World’s Best
Every funding decision is informed by a Scientific Advisory Board representing the highest tier of longevity, geroscience, and clinical research globally. Their role is not ceremonial — they review and guide final project selection at every grant cycle.
Our Scientific Advisory Board is independent of commercial interests and operates solely in service of scientific rigor and mission alignment. Members are selected for demonstrated excellence in longevity science, geroscience, and translational research.
Where Your Support Goes to Work
Philanthropy can drive change that neither governments nor industry will. Unlike most research philanthropy, LSF is singularly focused on optimizing health outcomes — not commercial returns. The science we fund is selected for its potential to accelerate progress on healthspan and lifespan. We measure success not in dollars deployed, but in healthier years of life added.
Foundation overhead is covered entirely by our founders — meaning every dollar you contribute flows directly to the science. Below are the areas where catalytic capital will have the greatest near-term impact.
The foundation of everything LSF does is a community of people who believe the science matters. No gift is too small — friends of LSF are the proof that longevity science is for everyone.
- Tax-deductible contribution subject to IRS guidelines — consult your tax advisor
- Direct your gift to your chosen research area
- 100% of your gift funds research — foundation operations are covered by our founders
- Access to LSF’s Education Platform
- Longevity Science Summit access
- Quarterly research updates from LSF + PIs
Research Builders are engaged supporters who want visibility into the science their capital funds. The relationship moves from donation to genuine partnership — you receive direct communication from research teams.
- All LSF Ally benefits
- Discounted Muhdo biological age testing
- Pre-publication research previews
- Quarterly research updates from LSF + PIs
Science Catalyst members step into a deeper relationship with LSF, gaining access to intelligence, relationships, and experiences at the intersection of science and community.
- All Research Builder benefits
- Quarterly LSF portfolio briefings
- 5 Private Hype vs. Reality scientific reviews per year
- In-person lab & research team visits
- First commercial investment rights into LSF research spinouts
Longevity Vanguards don’t just support LSF — they help shape it. You have a voice in the research agenda, a seat at the table where funding decisions are made, and a public position as one of the architects of longevity science’s future.
- All Science Catalyst benefits
- Observer seat at the grant review table
- Research co-design for a dedicated grant call
- Named grant call — your name on the science
- Summit panel participation
- Media participation & feature opportunity
- LongeVC network introductions & diligence access
LSF Founders Fund members are the people who make the entire mission possible at scale. In addition to every benefit above, Founders Fund members receive permanent recognition and co-investment access alongside LongeVC. You are not a donor. You are a founder.
- All Longevity Vanguard benefits
- Co-investment rights on LongeVC deals
- Permanent Founders Fund designation
- Named in LSF website, publications & research acknowledgments in perpetuity
- Deepest LongeVC network integration
Two offerings that set LSF apart from every other vehicle for longevity philanthropy.
Connecting Intention to Impact
If you have a dedicated desire to fund the best science in a specific area — Parkinson’s, women’s health, diabetes, cardiovascular aging — LSF becomes your trusted scientific advisor. We source from hundreds of research institutions and thousands of researchers globally, applying a rigorous, independent diligence process designed to surface the best early-stage science. Identifying the right researcher independently is next to impossible. We carry that burden for you, so your capital finds exactly the impact you intend.
Maximizing Every Dollar
When research is funded directly through a university, administrative overhead can at times exceed 100% of the cost of the research itself — meaning less than half your gift reaches the science. LSF has been able to reduce those administrative costs by over 75% in certain engagements. Your dollars go further, your impact is greater, and the science moves faster.
The healthspan-lifespan gap is not static — it is widening. The window to intercept these trajectories — through prevention science funded before the damage becomes irreversible — is open now. Every year of delay is measured in human suffering at population scale.
Our purpose is to step up. Where industry, investors, and governments seek profit, we prioritize impact-focused research, open access, and equity — and we strive to make longevity a right for all, not a privilege.
With catalytic funding, we are reshaping the global healthcare landscape by funding the world’s best science that will redefine aging and disease prevention, and transform the future of health for all.
It’s what you set in motion.